Literature DB >> 27007563

AMERICAN CUTANEOUS LEISHMANIASIS WITH UNUSUAL CLINICAL PRESENTATION AND RESPONSE TO TREATMENT.

Andrea Claudia Bekner Silva Fernandes1, Raíssa Bocchi Pedroso1, Eneide Aparecida Sabaini Venazzi2, Paulo Donizeti Zanzarini2, Sandra Mara Alessi Aristides2, Maria Valdrinez Campana Lonardoni2, Thaís Gomes Verzignassi Silveira2.   

Abstract

The clinical manifestations and prognosis of cutaneous leishmaniasis (CL) can be influenced by the immune response of the patient and the species of the parasite. A case of atypical clinical presentation of CL, with development of non-characteristic lesions, poor response to therapy, and a long time to resolution is reported. Confirmatory laboratory tests included parasite detection, indirect immunofluorescence, Montenegro skin test, polymerase chain reaction, and parasite identification by multilocus enzyme electrophoresis. The parasite was identified as Leishmania braziliensis. The lesion was unresponsive to three complete courses of N-methylglucamine antimoniate intramuscular, and to treatment with pentamidine. The patient did not tolerate amphotericin B. The lesion finally receded after treatment with intravenous N-methylglucamine antimoniate. It is essential to ensure the accuracy of diagnosis and the appropriate treatment, which can include the use a second choice drug or a different route of administration.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27007563      PMCID: PMC4804557          DOI: 10.1590/S1678-9946201658020

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  18 in total

1.  Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species.

Authors:  R Palacios; L E Osorio; L F Grajalew; M T Ochoa
Journal:  Am J Trop Med Hyg       Date:  2001 Mar-Apr       Impact factor: 2.345

2.  Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease.

Authors:  Steven Mings; Jill C Beck; Christopher Davidson; Andrew L Ondo; Stuart D Shanler; Jonathan Berman
Journal:  Am J Trop Med Hyg       Date:  2009-01       Impact factor: 2.345

Review 3.  Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis.

Authors:  Hiro Goto; José Angelo Lauletta Lindoso
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

4.  Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.

Authors:  H Bermúdez; E Rojas; L Garcia; P Desjeux; J-C Dujardin; M Boelaert; F Chappuis
Journal:  Ann Trop Med Parasitol       Date:  2006-10

Review 5.  [American cutaneous leishmaniasis].

Authors:  Bernardo Gontijo; Maria de Lourdes Ribeiro de Carvalho
Journal:  Rev Soc Bras Med Trop       Date:  2003-04-22       Impact factor: 1.581

Review 6.  Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis.

Authors:  F T Silveira; R Lainson; C M De Castro Gomes; M D Laurenti; C E P Corbett
Journal:  Parasite Immunol       Date:  2009-08       Impact factor: 2.280

7.  Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil.

Authors:  L H Guimarães; P R L Machado; E L Lago; D J Morgan; A Schriefer; O Bacellar; E M Carvalho
Journal:  Trans R Soc Trop Med Hyg       Date:  2009-05-28       Impact factor: 2.184

8.  American tegumentary leishmaniasis: an uncommon clinical and histopathological presentation.

Authors:  Adrilena Lopes Adriano; Paula Azevedo Borges Leal; Marcelle Parente Breckenfeld; Igor dos Santos Costa; Clarisse Almeida; Antônio Renê Diógenes de Sousa
Journal:  An Bras Dermatol       Date:  2013 Mar-Apr       Impact factor: 1.896

9.  American tegumentary leishmaniasis caused by Leishmania (Viannia) braziliensis: assessment of parasite genetic variability at intra- and inter-patient levels.

Authors:  Fernanda S Oliveira; Cláudia M Valete-Rosalino; Sandro J B Pacheco; Filipe A Carvalho Costa; Armando O Schubach; Raquel S Pacheco
Journal:  Parasit Vectors       Date:  2013-06-20       Impact factor: 3.876

10.  Cutaneous leishmaniasis with atypical clinical manifestations: Case report.

Authors:  Herintha Coeto Neitzke-Abreu; Mateus Sabaini Venazzi; Regiane Bertin de Lima Scodro; Paulo Donizeti Zanzarini; Andréa Claudia Bekner da Silva Fernandes; Sandra Mara Alessi Aristides; Thaís Gomes Verzignassi Silveira; Maria Valdrinez Campana Lonardoni
Journal:  IDCases       Date:  2014-07-27
View more
  2 in total

1.  Case Report: Atypical Cutaneous Leishmaniasis in a Patient with Mixed Leishmania guyanensis and Leishmania amazonensis Infection.

Authors:  Carina Scolari Gosch; Bruna Silva Resende; Célia Bastos Amorim; Cálita Pollyanna Marques; Ledice Inacia de Araújo Pereira; Sebastião Alves Pinto; Silvia Reni Bortolin Uliana; Adriano Cappellazzo Coelho; Fátima Ribeiro-Dias; Miriam Leandro Dorta
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

2.  Intercalated low doses of antimonials for disseminated cutaneous leishmaniasis caused by Leishmania guyanensis: A successful approach in Amazonas, Brazil.

Authors:  Aline Grasielli Monçale Campos; Louise Makarem Oliveira; Laísa Ezaguy de Hollanda; Valeska Albuquerque Francesconi do Valle; Fábio Francesconi do Valle
Journal:  JAAD Case Rep       Date:  2018-11-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.